2.08
-0.01(-0.48%)
Currency In USD
| Previous Close | 2.09 |
| Open | 2.1 |
| Day High | 2.16 |
| Day Low | 2.06 |
| 52-Week High | 33.98 |
| 52-Week Low | 1.15 |
| Volume | 579,698 |
| Average Volume | 821,856 |
| Market Cap | 100.48M |
| PE | -0.79 |
| EPS | -2.63 |
| Moving Average 50 Days | 2.23 |
| Moving Average 200 Days | 2.25 |
| Change | -0.01 |
If you invested $1000 in Cassava Sciences, Inc. (SAVA) 10 years ago, it would be worth $1,045.23 as of September 18, 2025 at a share price of $2.08. Whereas If you bought $1000 worth of Cassava Sciences, Inc. (SAVA) shares 5 years ago, it would be worth $1,444.44 as of September 18, 2025 at a share price of $2.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 25, 2025 12:00 PM GMT
AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tu
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
GlobeNewswire Inc.
Aug 07, 2025 11:30 AM GMT
Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN,
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
GlobeNewswire Inc.
Aug 04, 2025 11:30 AM GMT
Study in a TSC mouse model further demonstrates simufilam’s anti-seizure activityStudy conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout modelFirst clinical study for simufilam in TSC-related epilepsy expected to begin
Data not available